# US 9,872,875 B2 · Component and method for treating viral disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,872,875 B2
- Document ID: US9872875B2
- Status: Granted
- Kind: B2
- Application number: 14/384,075
- Filed: 2013-03-11
- Published: 2015-02-12
- Granted: 2018-01-23
- Earliest claimed: 2012-03-09
- Assignees: Honz Pharmaceutical Co., Ltd.
- Applicants: Institut Pasteur of Shanghai, Chinese Academy of Sciences
- Inventors: Altmeyer Ralf; Peijun Ren
- Web page: https://patentgrep.com/patent/US9872875B2

## CPC

- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 31/185: Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327)
- A61K 31/655: Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for treating viral infection includes administering to a subject in need thereof a composition containing P2X receptor antagonists. The methods may achieve preventive or therapeutic effect on hand foot and mouth disease by inhibiting viruses. The P2X receptor antagonists can inhibit infection by a positive-sense single-stranded RNA picornavirus. The virus may be an enterovirus or a Coxsackie virus, such as human enterovirus 71. The P2X receptor antagonist may be PPADS, iso-PPADS, PPNDS, Suramin, NF023, TNP-ATP, NF279, NF157, Evans Blue, an analog thereof, a derivative thereof, or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A method for alleviating or treating hand foot and mouth disease, comprising: administering to a subject in need thereof a composition comprising a P2X receptor antagonist, wherein the P2X receptor antagonist is selected from the group consisting of: PPADS, iso-PPADS, PPNDS, Suramin, NF023, TNP-ATP, NF279, NF157, Evans Blue, an analog thereof, a derivative thereof, and a pharmaceutically acceptable salt thereof, wherein a total daily dose of the P2X receptor antagonist is at 50-200 mg/kg body weight.

### Claim 2 (depends on 1)

The method of claim 1, wherein the administering is by oral administration, intravenous injection, intramuscular injection, or inhalation.

### Claim 3

A method for inhibiting infection by a positive-sense single-stranded RNA picornavirus that causes hand foot and mouth disease, comprising: administering to a subject in need thereof an effective amount of a P2X receptor antagonist, wherein the P2X receptor antagonist is selected from the group consisting of: PPADS, iso-PPADS, PPNDS, Suramin, NF023, TNT-ATP, NF279, NF157, Evans Blue, an analog thereof, a derivative thereof, and a pharmaceutically acceptable salt thereof, wherein a total daily dose of the P2X receptor antagonist is at 50-200 mg/kg body weight.

### Claim 4 (depends on 3)

The method of claim 3, wherein the subject is a human, a monkey, or a mouse.

### Claim 5 (depends on 3)

The method of claim 3, wherein the virus is an enterovirus or a Coxsackie virus.

### Claim 6 (depends on 3)

The method of claim 3, wherein the virus is an enterovirus A.

### Claim 7 (depends on 3)

The method of claim 3, wherein the virus is a human enterovirus 71.

### Claim 8 (depends on 3)

The method of claim 3, wherein the virus is a Coxsackie virus.

### Claim 9 (depends on 1)

The method of claim 1, wherein the P2X receptor antagonist is Suramin, total daily dose of Suramin is at 50 mg/kg body weight.

### Claim 10 (depends on 1)

The method of claim 1, wherein total daily dose is divided into several doses for administration in a day.

### Claim 11 (depends on 3)

The method of claim 3, wherein the P2X receptor antagonist is Suramin, total daily dose is of Suramin at 50 mg/kg body weight.

### Claim 12 (depends on 3)

The method of claim 3, wherein total daily dose is divided into several doses for administration in a day.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject is a human, a monkey, or a mouse.

### Claim 14 (depends on 3)

The method of claim 3, wherein the administering is by oral administration, intravenous injection, intramuscular injection, or inhalation.